ANIP | Ticker Profile - Titan Protect

ANIP

ANI Pharmaceuticals, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic · NGM

$81.11

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.9B

Total market value of the company

Trailing P/E

20.91

Premium valuation

Forward P/E

7.70

Based on estimated future earnings — lower means cheaper

Rev Growth

+20.5%

Year-over-year revenue change

Profit Margin

10.0%

How much profit the company keeps from each dollar of revenue

ROE

18.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$110.00

+36% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 8 analysts covering this stock

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

https://www.anipharmaceuticals.com

Country: United States Employees: 970 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.522

Good returns relative to risk taken

Kelly Fraction

0.0435

Modest edge detected — smaller position warranted

Calmar Ratio

0.470

Drawdown risk outweighs the returns — higher risk profile

Annual Return

13.5%

Historical annualised return based on price data

Max Drawdown

-28.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.46

Very low correlation to market moves

52W High

$99.50

18% below the year high

52W Low

$57.33

41% above the year low

Avg Volume

375,981

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

19.4%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$3.91

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

112.08

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.12

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

2.43

Like current ratio but excludes inventory — stricter test

Gross Margin

60.8%

Revenue left after cost of goods — higher means pricing power

Operating Margin

16.3%

Profit from core operations before interest and tax

Free Cash Flow

$140M

Positive — the business generates more cash than it spends

Revenue (TTM)

$924M

Total revenue over the last 12 months

Net Income

$84M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$124.00

Target Median

$110.00

Target Low

$90.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go